List of Excipients in Branded Drug NEPHRAMINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
B Braun Medical Inc	NEPHRAMINE	histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine, cysteine, and sodium bisulfite	0264-1909	SODIUM BISULFITE
B Braun Medical Inc	NEPHRAMINE	histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine, cysteine, and sodium bisulfite	0264-1909	WATER

Nephramine Excipient Strategy and Commercial Opportunities in Renal Nutrition

Last updated: August 23, 2026

NephrAmine is a renal-specific parenteral amino-acid formulation used when oral or enteral nutrition is inadequate or impossible in patients with renal insufficiency. Its commercial value is driven less by composition-of-matter patents than by sterile manufacturing, hospital formulary access, renal-nutrition evidence, supply reliability, and compatibility with dialysis and parenteral-nutrition workflows. The strongest product strategy is a low-excipient, sulfite-controlled formulation supported by ready-to-use presentations, validated container systems, and reliable institutional supply.

What is NephrAmine and how is it used?

NephrAmine is an intravenous amino-acid injection intended to provide nitrogen and amino acids to patients with renal impairment who require parenteral nutrition. The marketed formulation is commonly identified as NephrAmine 5.4%, corresponding to approximately 5.4 g of amino acids per 100 mL of solution.[1]

The product is used within a broader parenteral-nutrition regimen. It does not replace the need for individualized administration of dextrose, lipid emulsion, vitamins, trace elements, and electrolytes. Clinicians adjust the regimen according to renal function, dialysis status, nitrogen balance, fluid restrictions, serum electrolytes, and metabolic tolerance.

What is the active pharmaceutical ingredient?

NephrAmine does not contain a single small-molecule active ingredient. Its active component is a defined mixture of essential and nonessential amino acids, including amino acids such as:

• Leucine
• Isoleucine
• Valine
• Lysine
• Methionine
• Phenylalanine
• Threonine
• Tryptophan
• Histidine
• Arginine
• Alanine
• Glycine
• Proline
• Serine
• Tyrosine

The formulation is therefore best analyzed as a sterile compounded nutrient product rather than as a conventional tablet or injectable small molecule.

What excipients are used in NephrAmine?

The core excipient strategy is limited. Injectable amino-acid products generally avoid unnecessary inactive ingredients because patients with renal dysfunction have reduced capacity to clear certain excipients and often receive multiple intravenous products simultaneously.

The product labeling identifies water for injection as the vehicle and uses pH adjustment and stabilization components. Sodium bisulfite is identified in labeling for the formulation as a stabilizer or antioxidant, and the product carries the associated sulfite-sensitivity warning.[1]

Formulation element	Function	Strategic relevance
Water for injection	Solvent and vehicle	Requires sterile, pyrogen-controlled water system
Sodium bisulfite	Antioxidant or stabilizer	Protects susceptible amino acids but creates sulfite-sensitivity exposure
pH-adjusting agent	Controls solution stability and tolerability	Affects degradation, precipitation, and container compatibility
Amino-acid mixture	Active nutrient content	Determines nitrogen delivery and renal-nutrition positioning
Container closure system	Maintains sterility and stability	Important for oxygen ingress, leachables, adsorption, and shelf life

NephrAmine’s formulation should not be evaluated only by its inactive-ingredient list. The commercial formulation includes the container, overwrap, port design, sterilization cycle, oxygen control, and storage conditions. These elements can determine whether a competing product obtains a practical hospital advantage.

What excipients create the main safety issue?

Sulfites are the principal excipient-related safety concern. Sulfite exposure can cause hypersensitivity reactions, particularly in susceptible individuals with asthma. The labeling warning creates a potential commercial opening for a sulfite-free or lower-sulfite formulation if the product can achieve equivalent stability and shelf life without sacrificing amino-acid integrity.[1]

A sulfite-free strategy would require evidence addressing:

1. Amino-acid degradation over the proposed shelf life.
2. Formation of oxidation products.
3. Subvisible and visible particulate matter.
4. Sterility assurance.
5. Container oxygen transmission.
6. Compatibility with automated compounding systems.
7. Stability after admixture with dextrose, lipids, electrolytes, vitamins, and trace elements.

Removing sodium bisulfite without replacing its stabilizing function may reduce tolerability for some patients but shorten shelf life or increase degradation. The commercial opportunity exists only if the sponsor can solve both problems through oxygen-reduced manufacturing, improved container closure, pH optimization, or an alternative antioxidant system.

What formulations are protected by NephrAmine’s product strategy?

NephrAmine is primarily protected by formulation know-how and manufacturing controls rather than by a high-value patent estate. Relevant protection areas include:

• Amino-acid concentration and ratio.
• pH range.
• Antioxidant selection.
• Oxygen-control process.
• Sterile filtration or terminal sterilization parameters.
• Container composition.
• Bag and port configuration.
• Storage temperature and excursion limits.
• Admixture compatibility.
• Filling and sealing process.
• Shelf-life specification.

A reformulated competitor could seek differentiation through:

• Sulfite-free presentation.
• Lower-volume, higher-concentration bag.
• Dual-chamber or multi-chamber delivery system.
• Ready-to-use renal nutrition formulation.
• Latex-free or DEHP-reduced packaging.
• Smaller bags for fluid-restricted patients.
• Pharmacy-friendly ports for automated compounding.
• Extended in-use stability after opening or admixture.

The main intellectual-property risk is not likely to arise from the amino-acid ingredients themselves. Amino acids are established nutrients, and the individual compounds are long out of patent protection. Any meaningful patent position would more likely cover a particular ratio, stabilizer system, container, manufacturing process, or use in a defined renal-nutrition population.

When does NephrAmine lose exclusivity?

NephrAmine’s commercial exclusivity is unlikely to be governed by a conventional remaining composition-of-matter patent term. The product belongs to a mature injectable nutrient category in which competition is shaped by regulatory approval, manufacturing capacity, hospital contracts, and supply continuity.

Exclusivity element	NephrAmine relevance
New chemical entity exclusivity	Not commercially relevant to an established amino-acid mixture
Biosimilar exclusivity	Not applicable
Composition-of-matter patent	Unlikely to be the main barrier
Formulation patent	Possible, but value depends on claim scope and enforceability
Method-of-use patent	Possible for defined renal-nutrition use, but likely narrow
Regulatory exclusivity	Depends on the approved application and product history
Manufacturing barrier	High relative to the ingredient cost
Hospital purchasing barrier	High in an institutional product category

A competitor can therefore enter without overcoming a major active-ingredient patent, but it still must demonstrate injectable quality, sterility, stability, labeling compliance, and commercial supply. FDA requirements for parenteral products apply even when the ingredients are familiar nutrients.[2]

What is the Orange Book status of NephrAmine?

The Orange Book is most relevant to approved drug products with listed patents and recognized exclusivity. A conventional amino-acid injection may have limited or no patent-based Orange Book protection compared with patented small-molecule drugs.[3]

For a NephrAmine competitor, the principal regulatory questions are:

• Whether the reference product has an FDA-recognized reference listing.
• Whether an ANDA pathway is available.
• Whether the proposed product is sufficiently equivalent in formulation, concentration, route, and presentation.
• Whether the applicant must use a 505(b)(2) application because of formulation, indication, or product differences.
• Whether the reference product’s labeling and product history create additional clinical or quality requirements.

The product is not a biologic. Biosimilar litigation, reference-product exclusivity under the Public Health Service Act, and interchangeable-biologic substitution do not apply. Competition is more likely to involve ANDA or 505(b)(2) strategies, depending on the product’s regulatory classification and the proposed differences.[2]

Are there Paragraph IV challenges to NephrAmine?

Paragraph IV litigation is generally less likely to be the principal competitive issue for a mature amino-acid injection than for a patented oral drug. A Paragraph IV challenge would matter only if an applicable Orange Book-listed patent were identified for the reference product.

The higher-probability competitive routes are:

1. An approved generic or therapeutically equivalent injectable product.
2. A 505(b)(2) product with a modified excipient system or container.
3. A renal-nutrition product marketed through a different regulatory or institutional pathway.
4. A hospital-compounded formulation, subject to applicable compounding rules.
5. A contract-manufactured product supplied under private-label or institutional arrangements.

The absence of a major Paragraph IV event does not eliminate entry risk. In sterile injectables, commercial substitution can occur through formulary replacement, purchasing contracts, or shortage-driven sourcing without a highly publicized patent case.

How strong is the patent estate for NephrAmine?

The patent estate is likely weaker than the manufacturing and market-access estate.

Patent-strength assessment

Asset category	Likely strength	Commercial impact
Amino-acid composition	Low	Ingredients are established and broadly available
General renal-nutrition use	Low to moderate	Broad claims face prior-art and enablement pressure
Specific amino-acid ratio	Moderate if clinically supported	Could differentiate a targeted formulation
Sulfite-free stabilization	Moderate to strong if technically novel	Potentially valuable for safety and shelf life
Oxygen-control manufacturing	Moderate	Can protect process know-how more effectively than broad claims
Container and port design	Moderate	Relevant to hospital workflow and compatibility
Ready-to-use admixture format	Moderate to strong	Could support operational differentiation
Manufacturing know-how	Strong in practice, weak as public patent protection	Difficult to replicate quickly

A sponsor pursuing new intellectual property should focus on narrow, technically defensible claims. Strong candidates include a specific stabilizer-free formulation with defined degradation limits, a renal-specific amino-acid ratio supported by clinical data, or a container system that preserves product quality under realistic storage and administration conditions.

What commercial opportunities exist for NephrAmine competitors?

Can a sulfite-free NephrAmine competitor succeed?

Yes, if it demonstrates a meaningful clinical or operational advantage. Sulfite avoidance alone may not support premium pricing unless hospitals can connect it to patient safety, formulary policy, or reduced adverse-event risk.

The strongest positioning would combine sulfite avoidance with:

• Equivalent or longer shelf life.
• Lower oxygen exposure.
• Reduced discoloration.
• Improved compatibility with parenteral-nutrition admixtures.
• Simplified pharmacy preparation.
• Consistent national supply.
• Smaller-volume presentations.

Is a concentrated renal amino-acid formulation commercially attractive?

A more concentrated product could address fluid restriction, particularly in critically ill patients receiving dialysis. The product would need to maintain acceptable osmolarity, venous-access requirements, stability, and infusion tolerability.

The commercial tradeoff is clear:

• Higher concentration reduces fluid burden.
• Higher osmolarity may restrict peripheral administration.
• Greater concentration can increase precipitation and compatibility risks.
• Smaller bags may reduce waste but increase unit manufacturing cost.

Can ready-to-use or multi-chamber products capture market share?

Ready-to-use systems can create a stronger market position than a simple bottle-for-bottle generic. Hospitals value products that reduce compounding labor, preparation errors, contamination risk, and inventory complexity.

Potential formats include:

• Single-compartment amino-acid bags for pharmacy compounding.
• Multi-chamber bags with amino acids and dextrose.
• Dialysis-compatible renal nutrition systems.
• Small-volume presentations for fluid-restricted patients.
• Pharmacy bulk packages where permitted.
• Unit-dose bags for intensive-care use.

These products require extensive compatibility and stability testing. The technical burden is higher, but the resulting differentiation is harder for a commodity competitor to copy.

What manufacturing and IP barriers affect NephrAmine competition?

Sterile injectable manufacturing is the main entry barrier. A successful competitor must manage:

• Raw-material qualification for pharmaceutical-grade amino acids.
• Control of bioburden and endotoxin.
• Sterile filling and container closure integrity.
• Particulate control.
• Amino-acid degradation and oxidation.
• pH drift during storage.
• Extractables and leachables.
• Transport and temperature excursions.
• Supply continuity for all amino-acid components.
• FDA inspection and current good manufacturing practice compliance.[4]

Amino acids are individually available from multiple suppliers, but a finished sterile product depends on coordinated sourcing and validated process control. A manufacturer with existing parenteral-nutrition infrastructure has a material advantage over a new entrant.

Trade secrets may be more valuable than patents in this category. Process parameters, oxygen-management controls, fill accuracy, sterilization conditions, and container-closure performance can be difficult to reproduce from public patent documents.

What licensing deals could support NephrAmine expansion?

Potential licensing opportunities include:

• Regional licensing to established parenteral-nutrition manufacturers.
• Contract manufacturing for hospital systems.
• Private-label supply to group purchasing organizations.
• Licensing of a sulfite-free stabilization platform.
• Co-development of multi-chamber renal nutrition.
• Distribution agreements with dialysis providers.
• Technology transfer for local manufacture in markets dependent on imported sterile products.

The most valuable deal structure would likely combine formulation rights with manufacturing capacity and hospital distribution. A patent-only license would have limited value unless it covered a clinically meaningful formulation or delivery system.

What generic launch scenarios exist for NephrAmine?

Scenario 1: Commodity injectable entry

A competitor launches a conventional amino-acid injection with similar concentration and presentation. Price pressure is high, and differentiation depends on supply reliability and contracting.

Scenario 2: Sulfite-free premium entry

A competitor launches a sulfite-free product with equivalent shelf life. The product targets hospitals, intensive-care units, and patients with sulfite sensitivity. The opportunity is narrower but supports stronger clinical messaging.

Scenario 3: Concentrated, low-volume entry

A higher-concentration product targets fluid-restricted dialysis and critical-care patients. Regulatory and compatibility requirements are higher, but hospital value can be greater.

Scenario 4: Ready-to-use renal nutrition platform

A manufacturer supplies a multi-chamber or pharmacy-ready product. This strategy competes on labor reduction, medication-safety controls, and workflow efficiency rather than amino-acid price.

Scenario 5: Supply-driven substitution

A competitor gains share during shortages or allocation events. Hospitals may retain the substitute after supply normalizes if conversion costs are low and clinical performance is acceptable.

How does NephrAmine compare with general amino-acid injections?

Attribute	NephrAmine-type renal formulation	General adult amino-acid injection
Target population	Renal insufficiency and dialysis-related nutrition needs	Broad parenteral-nutrition population
Positioning	Renal-specific amino-acid support	General nitrogen and amino-acid replacement
Excipient strategy	Minimal excipients, renal-sensitive safety considerations	Similar sterile formulation priorities
Differentiation	Renal indication, concentration, amino-acid profile	Broad hospital and nutrition use
Patent risk	Generally limited	Generally limited
Main barrier	Sterile manufacturing and institutional adoption	Sterile manufacturing and broad competition
Commercial opportunity	Specialized renal nutrition	Larger but more crowded market

Key Takeaways

• NephrAmine is a renal-specific sterile amino-acid injection, not a biologic and not a conventional patented small molecule.
• Its main commercial defenses are manufacturing quality, supply reliability, hospital access, and product familiarity.
• Sodium bisulfite is the leading excipient-related differentiation point because it creates a sulfite-sensitivity concern.
• A sulfite-free formulation could command strategic value if it preserves shelf life and amino-acid stability.
• Concentrated, low-volume, ready-to-use, and multi-chamber presentations offer stronger differentiation than a basic generic copy.
• Paragraph IV and biosimilar risks are likely less important than ANDA or 505(b)(2) competition, hospital contracting, and sterile-injectable supply dynamics.
• The most defensible intellectual property would cover a technically demonstrated formulation, stabilization system, container, or manufacturing process.
• Licensing value is highest when formulation technology is paired with established sterile manufacturing and institutional distribution.

FAQs

Is NephrAmine an electrolyte-containing renal nutrition product?

NephrAmine is primarily an amino-acid injection. Electrolytes, dextrose, lipids, vitamins, and trace elements are generally managed separately or added according to the patient’s individualized parenteral-nutrition plan.[1]

Could a manufacturer patent a sulfite-free NephrAmine formulation?

A manufacturer could pursue patent protection for a specific sulfite-free composition or stabilization system if it is novel, non-obvious, and supported by reproducible stability data. Broad claims covering sulfite removal alone would face substantial validity pressure.

Would NephrAmine be subject to biosimilar competition?

No. NephrAmine is not a biologic. The relevant competitive pathways are generic-drug or 505(b)(2) pathways, subject to the product’s regulatory classification and reference-product status.[2]

What hospital buyers are most likely to value a new NephrAmine product?

Hospital pharmacies, intensive-care units, dialysis programs, and group purchasing organizations are likely to value reliable supply, reduced preparation burden, low-volume options, compatibility with automated compounding, and a clear sulfite or container-safety advantage.

Is the amino-acid ingredient cost the main determinant of NephrAmine pricing?

No. The finished-product economics are heavily influenced by sterile filling, quality control, container systems, validation, regulatory compliance, distribution, shortage risk, and hospital contracting. The amino acids themselves are established commodity-like inputs.

References

1. U.S. Food and Drug Administration. (n.d.). NephrAmine 5.4% amino acid injection prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
3. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
4. U.S. Food and Drug Administration. (2023). Current good manufacturing practice for finished pharmaceuticals, 21 C.F.R. Parts 210 and 211.